PerkinElmer to Acquire In-Vitro Diagnostics Company Immunodiagnostic Systems Holdings PLC
Endocrinology testing specialist expands PerkinElmer’s immunodiagnostics segment WALTHAM, Mass.–(BUSINESS WIRE)–May 17, 2021– PerkinElmer, Inc. (NYSE: PKI) (“PerkinElmer”) and Immunodiagnostic Systems Holdings PLC (LSE: IHS) (“IDS”) are pleased to announce that they have reached an agreement on the terms of a recommended all cash offer whereby PerkinElmer will acquire IDS for approximately $155 million (£110 Million).... Read more